Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO29551 | Mori fructus | NA | NA | NA | TCMSP* |
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT567 | Individual Protein | Matrix metalloproteinase 3 | Homo sapiens | Inhibition | = | 7 | % | 21189019 |
NPT150 | Individual Protein | Anthrax lethal factor | Bacillus anthracis | Inhibition | = | 8 | % | 21189019 |
NPT270 | Individual Protein | Nitric oxide synthase, inducible | Mus musculus | Inhibition | = | 8 | % | 21189019 |
NPT280 | Individual Protein | Matrix metalloproteinase 9 | Homo sapiens | Inhibition | = | 1 | % | 21189019 |
NPT568 | Individual Protein | Matrix metalloproteinase-2 | Homo sapiens | Inhibition | = | -7 | % | 21189019 |
NPT569 | Individual Protein | Matrix metalloproteinase 8 | Homo sapiens | Inhibition | = | 11 | % | 21189019 |
NPT570 | Individual Protein | Arachidonate 5-lipoxygenase | Homo sapiens | Inhibition | = | 24 | % | 21189019 |
NPT69 | Individual Protein | Matrix metalloproteinase-1 | Homo sapiens | Inhibition | = | 13 | % | 21189019 |
NPT43 | Individual Protein | Tyrosinase | Agaricus bisporus | Inhibition | = | -4 | % | 21189019 |
NPT947 | Individual Protein | Carbonic anhydrase I | Homo sapiens | Ki | = | 57760 | nM | 26073005 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC248627 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.7879 | Intermediate Similarity | NPC260919 |
0.7373 | Intermediate Similarity | NPC27699 |
0.6933 | Remote Similarity | NPC224632 |
0.6917 | Remote Similarity | NPC163105 |
0.6897 | Remote Similarity | NPC314440 |
0.6897 | Remote Similarity | NPC118135 |
0.6753 | Remote Similarity | NPC278874 |
0.6667 | Remote Similarity | NPC105758 |
0.6667 | Remote Similarity | NPC476688 |
0.6667 | Remote Similarity | NPC476686 |
0.6667 | Remote Similarity | NPC75844 |
0.6603 | Remote Similarity | NPC164664 |
0.656 | Remote Similarity | NPC329046 |
0.6519 | Remote Similarity | NPC208060 |
0.6481 | Remote Similarity | NPC144114 |
0.638 | Remote Similarity | NPC477891 |
0.6194 | Remote Similarity | NPC139776 |
0.6154 | Remote Similarity | NPC230805 |
0.6092 | Remote Similarity | NPC208751 |
0.6059 | Remote Similarity | NPC472289 |
0.6058 | Remote Similarity | NPC248007 |
0.5932 | Remote Similarity | NPC326364 |
0.5912 | Remote Similarity | NPC5707 |
0.5814 | Remote Similarity | NPC254762 |
0.5736 | Remote Similarity | NPC222061 |
0.5734 | Remote Similarity | NPC287876 |
0.5726 | Remote Similarity | NPC476128 |
0.5664 | Remote Similarity | NPC14330 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC248627 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.84 | Intermediate Similarity | NPD9187 | Approved |
0.7879 | Intermediate Similarity | NPD8825 | Phase 2 |
0.7879 | Intermediate Similarity | NPD59 | Approved |
0.7576 | Intermediate Similarity | NPD533 | Approved |
0.7373 | Intermediate Similarity | NPD8571 | Phase 3 |
0.7239 | Intermediate Similarity | NPD9550 | Approved |
0.7239 | Intermediate Similarity | NPD9551 | Approved |
0.6887 | Remote Similarity | NPD444 | Approved |
0.6667 | Remote Similarity | NPD8566 | Approved |
0.6532 | Remote Similarity | NPD9071 | Phase 3 |
0.6389 | Remote Similarity | NPD852 | Discontinued |
0.6387 | Remote Similarity | NPD4143 | Clinical (unspecified phase) |
0.6204 | Remote Similarity | NPD9366 | Approved |
0.6154 | Remote Similarity | NPD9714 | Clinical (unspecified phase) |
0.6148 | Remote Similarity | NPD306 | Approved |
0.6058 | Remote Similarity | NPD9084 | Phase 2 |
0.5912 | Remote Similarity | NPD8830 | Phase 3 |
0.5833 | Remote Similarity | NPD9083 | Clinical (unspecified phase) |
0.5763 | Remote Similarity | NPD6594 | Discontinued |
0.576 | Remote Similarity | NPD9194 | Approved |
0.576 | Remote Similarity | NPD9193 | Approved |
0.575 | Remote Similarity | NPD8565 | Clinical (unspecified phase) |
0.5734 | Remote Similarity | NPD8829 | Clinical (unspecified phase) |
0.5698 | Remote Similarity | NPD7419 | Discontinued |
0.5671 | Remote Similarity | NPD761 | Approved |
0.5671 | Remote Similarity | NPD741 | Approved |
0.5644 | Remote Similarity | NPD5925 | Phase 1 |
PubChem CID   | 12283 |
ChEMBL   | CHEMBL1650614 |
ZINC   |
Molecular Weight:   | 126.04 |
ALogP:   | -0.4811 |
MLogP:   | 1.57 |
XLogP:   | 0.035 |
# Rotatable Bonds:   | 3 |
Polar Surface Area:   | 66.24 |
# H-Bond Aceptor:   | 2 |
# H-Bond Donor:   | 2 |
# Rings:   | 1 |
# Heavy Atoms:   | 9 |